c7d11d59294490e724c7aa32d337301ee56cc760
BTG1.md
| ... | ... | @@ -47,10 +47,6 @@ timeline |
| 47 | 47 | |:--------:|:----------:|:--------:|:------------------------------------------------------------------------------------------:|:------------------:| |
| 48 | 48 | |chr12 |92537999 |92539598|[TSS](https://genome.ucsc.edu/s/rdmorin/GAMBL%20hg19?position=chr12%3A92537999%2D92539598)|active_promoter | |
| 49 | 49 | |
| 50 | -> [!NOTE] |
|
| 51 | -> First described in BL in 2022 by [Burkhardt B](https://pubmed.ncbi.nlm.nih.gov/35794096). First described in DLBCL in 2011 by [Morin RD](https://pubmed.ncbi.nlm.nih.gov/21796119) |
|
| 52 | - |
|
| 53 | - |
|
| 54 | 50 | ## BTG1 Hotspots |
| 55 | 51 | |
| 56 | 52 | *Q36H* Conditional knock-in mouse models expressing the BTG1 Q36H mutation in B cells have shown that these mutations lead to earlier onset of lymphoma, shorter survival, and dysplastic B cell infiltration into non-lymphoid organs. These findings reinforce the role of BTG1 mutations in enhancing lymphoma aggressiveness.<sup>3</sup> |